The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

This study has been completed.
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01171768
First received: July 16, 2010
Last updated: July 20, 2011
Last verified: July 2011
  Purpose

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.


Condition
Inflammatory Lung Diseases
Hemoptysis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis [ Time Frame: up to 7 days after enrollment ] [ Designated as safety issue: Yes ]
    We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.


Secondary Outcome Measures:
  • to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia. [ Time Frame: up to 7 days after enrollment ] [ Designated as safety issue: Yes ]
    We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.


Estimated Enrollment: 52
Study Start Date: June 2008
Study Completion Date: December 2010
Groups/Cohorts
patients with hemoptysis within 2 weeks
patients without hemoptysis within 2 years

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, peumonia and post-tuberculosis destroyed lung

Criteria

Inclusion Criteria:

  • patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung

Exclusion Criteria:

  • patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01171768

Locations
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Samsung Medical Center
  More Information

No publications provided

Responsible Party: Sang-Won Um, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01171768     History of Changes
Other Study ID Numbers: 2008-05-043
Study First Received: July 16, 2010
Last Updated: July 20, 2011
Health Authority: Korea: Institutional Review Board

Keywords provided by Samsung Medical Center:
Vascular endothelial growth factor
angiopoietin-2

Additional relevant MeSH terms:
Hemoptysis
Lung Diseases
Respiratory Tract Diseases
Hemorrhage
Pathologic Processes
Signs and Symptoms, Respiratory
Signs and Symptoms

ClinicalTrials.gov processed this record on August 26, 2014